In vitro studies on controlled-release cellulose acetate films for local delivery of chlorhexidine, indomethacin, and meloxicam

被引:21
作者
Çetin, EÖ
Buduneli, N [1 ]
Atlihan, E
Kirilmaz, L
机构
[1] Ege Univ, Sch Dent, Dept Periodontol, TR-35100 Izmir, Turkey
[2] Ege Univ, Sch Pharm, Dept Biopharmaceut & Pharmacokinet, Izmir, Turkey
关键词
cellulose acetate films; chlorhexidine gluconate; controlled drug delivery; indomethacin; meloxicam; periodontal disease; rate measurements;
D O I
10.1111/j.1600-051X.2004.00620.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Delivery of medications into periodontal pockets to suppress or eradicate the pathogenic microbiota or modulate the inflammatory response, thereby limiting periodontal tissue destruction, has attracted significant interest with the purpose of effective periodontal treatment. However, no study has previously attempted to develop a controlled-release formulation of anti-inflammatory agents to be used in the field of periodontology. The aim of the present study was to examine the in vitro release profile of chlorhexidine gluconate, indomethacin, and meloxicam from cellulose acetate films. Methods: Cellulose acetate films containing chlorhexidine gluconate, indomethacin, and meloxicam were prepared and cut in a form to fit to the periodontal pocket anatomy. The release of active agents was studied in 10 ml artificial saliva at 37degreesC. Apparatus Vibrax was used at 150 r.p.m. Determinations were carried out spectrophotometrically and the release profiles were plotted as a function of time. Results: The formulations showed two different release patterns for a total observation period of approximately 120 h. When the formulations of the three active agents were compared, the release patterns of meloxicam and chlorhexidine gluconate were found to be similar, while the indomethacin-containing formulation exhibited the fastest release rate. Conclusions: As a conclusion, cellulose acetate may be a suitable inert material for obtaining a prolonged local release of various anti-inflammatory agents like meloxicam. Further in vitro and in vivo studies are required before starting clinical applications of these controlled-release formulations of anti-inflammatory agents.
引用
收藏
页码:1117 / 1121
页数:5
相关论文
共 36 条
[1]   THE DEVELOPMENT AND INVITRO EVALUATION OF ACRYLIC STRIPS AND DIALYSIS TUBING FOR LOCAL-DRUG DELIVERY [J].
ADDY, M ;
RAWLE, L ;
HANDLEY, R ;
NEWMAN, HN ;
COVENTRY, JF .
JOURNAL OF PERIODONTOLOGY, 1982, 53 (11) :693-699
[2]  
Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1
[3]   Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats [J].
Bezerra, MM ;
de Lima, V ;
Alencar, VBM ;
Vieira, IB ;
Brito, GAC ;
Ribeiro, RA ;
Rocha, FAC .
JOURNAL OF PERIODONTOLOGY, 2000, 71 (06) :1009-1014
[4]   Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy [J].
Buduneli, N ;
Vardar, S ;
Atilla, G ;
Sorsa, T ;
Luoto, H ;
Baylas, H .
JOURNAL OF PERIODONTOLOGY, 2002, 73 (01) :103-109
[5]  
BUDUNELI N, 2001, ANKARA U DISHEKIMLIG, V28, P161
[6]  
BUDUNELI N, 2001, ANKARA U DISHEKIMLIG, V28, P287
[7]  
Engelhardt G, 1996, BRIT J RHEUMATOL, V35, P4
[8]  
FIORELLINI JP, 1992, J PERIODONTOL, V66, P870
[9]   SALIVARY PAF LEVELS CORRELATE WITH THE SEVERITY OF PERIODONTAL INFLAMMATION [J].
GARITO, ML ;
PRIHODA, TJ ;
MCMANUS, LM .
JOURNAL OF DENTAL RESEARCH, 1995, 74 (04) :1048-1056
[10]  
GOFFIN G, 1998, INT DENT REV, P1